Safe Doses of Olaparib Plus Gemcitabine for Advanced Solid Tumors Determined
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that intermittent dosing of olaparib 100mg twice daily plus gemcitabine 600mg/m2 is safe for the treatment of patients with advanced solid tumors, while continuous dosing of olaparib or in combination with doses of gemcitabine larger than 600mg/m2 are not.
In this phase 1, dose-escalation study, 66 patients with advanced solid tumors were enrolled. Of those, 44 received olaparib 50-200mg capsules twice daily intermittently or continuously on days 1-14 every 28 days in combination with gemcitabine 600-800mg/m2 on days 1,8, 15, and 22 for cycle 1 and days 1, 8, and 15 for subsequent cycles.
Twelve patients participated in the tablet cohort, in which patients received the same regimen except olaparib was given in tablet formulation at 100mg daily or twice daily. In addition, 22 patients with locally advanced or metastatic pancreatic cancer were randomly assigned to received olaparib plus gemcitabine or gemcitabine 1000mg/m2 alone.
Results showed that patients in the dose-escalation cohorts tolerated the regimens well, but 81% of patients treated with olaparib capsules with gemcitabine experienced severe adverse events; the most common adverse events were hematological toxicities.
In regard to efficacy, no differences were observed by researchers.
Intermittent dosing of olaparib plus gemcitabine is safe for the treatment of patients with advanced solid tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma